双份无关脐血对比单倍体骨髓移植:BMT CTN 1101 试验
该随机二期试验纳入368例化疗敏感淋巴瘤或缓解期急性白血病患者,比较双份无关脐血与单倍体骨髓移植。
核心结论
- 双份无关脐血与单倍体骨髓移植在2年无进展生存率上无统计学显著差异。
- 但脐血移植的非复发死亡率和总生存率等次要终点劣于单倍体骨髓移植。
研究设计与样本
- 随机二期试验,2012年6月至2018年6月纳入368例18至70岁化疗敏感淋巴瘤或缓解期急性白血病患者,随机分为脐血组(n=186)和单倍体组(n=182)。
- 两组均采用减低强度预处理,方案为全身照射联合环磷酰胺和氟达拉滨。
- 脐血移植GVHD预防采用环孢素联合霉酚酸酯;单倍体移植采用移植后环磷酰胺、他克莫司和霉酚酸酯。
临床怎么用
- 在减低强度预处理下,两种供者来源均可扩展移植可及性。
- 次要终点(包括总生存)支持优先选择单倍体骨髓供者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Results of 2 parallel phase 2 trials of transplantation of unrelated umbilical cord blood (UCB) or bone marrow (BM) from HLA-haploidentical relatives provided equipoise for direct comparison of these donor sources. Between June 2012 and June 2018, 368 patients aged 18 to 70 years with chemotherapy-sensitive lymphoma or acute leukemia in remission were randomly assigned to undergo UCB (n = 186) or haploidentical (n = 182) transplant. Reduced-intensity conditioning comprised total-body irradiation with cyclophosphamide and fludarabine for both donor types. Graft-versus-host disease prophylaxis for UCB transplantation was cyclosporine and mycophenolate mofetil (MMF) and for haploidentical transplantation, posttransplant cyclophosphamide, tacrolimus, and MMF. The primary end point was 2-year progression-free survival (PFS). Treatment groups had similar age, sex, self-reported ethnic origin, performance status, disease, and disease status at randomization. Two-year PFS was 35% (95% confidence interval [CI], 28% to 42%) compared with 41% (95% CI, 34% to 48%) after UCB and haploidentical transplants, respectively (P = .41). Prespecified analysis of secondary end points recorded higher 2-year nonrelapse mortality after UCB, 18% (95% CI, 13% to 24%), compared with haploidentical transplantation, 11% (95% CI, 6% to 16%), P = .04. This led to lower 2-year overall survival (OS) after UCB compared with haploidentical transplantation, 46% (95% CI, 38-53) and 57% (95% CI 49% to 64%), respectively (P = .04). The trial did not demonstrate a statistically significant difference in the primary end point, 2-year PFS, between the donor sources. Although both donor sources extend access to reduced-intensity transplantation, analyses of secondary end points, including OS, favor haploidentical BM donors. This trial was registered at www.clinicaltrials.gov as #NCT01597778.
引用
- Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021. PMID: 33475736. doi:10.1182/blood.2020007535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。